GenScript Biotech, a provider of life-science research tools and services, is partnering with Allozymes, a Singapore-based biotech startup, with aims to accelerate the enzyme discovery and development process.
In the partnership, GenScript will provide the mutant libraries construction and expression, while Allozymes will provide ultra-high-throughput screening for applications across various industries, including pharmaceuticals.
Naturally occurring enzymes and microbes are used for biomedical purposes and in the field of biotechnology.
The development of synthetic biology has provided a solution to engineer custom microbes into cell factories that can produce a product with improved properties. This approach involves the generation of mutant libraries followed by a high-throughput screening technology.
Allozymes is a deep-tech company that offers directed evolution in the microfluidic system so that up to ten million variants can be screened per day.